A consortium of new and previous backers led by Life Sciences Partners (LSP) has invested $38.5m in France-based DNA Script, a manufacturer of synthetic DNA.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
Fund targets companies operating in the healthcare industry, primarily pharma, medtech and outsourced services